Bacterial Keratitis. Part 2. Topical Aspects of Treatment

Bacterial keratitis (BC) is a threatening condition for the anatomy and function of the eyeball and requires an immediate complex of therapeutic measures. Effective treatment that preserves the anatomical and functional result of the organ of vision, including various non-surgical and surgical methods, is the basis for the treatment of CD. Drug therapy includes, first of all, massive etiotropic therapy, which is usually represented by broad-spectrum antibiotics, antiseptics and anti-inflammatory drugs. These combinations make it possible to competitively influence all links of the pathological process, showing an additive effect. Promising non-surgical means in the fight against bacterial infection of the cornea, in particular with resistant microorganisms, is the use of Quantum dots, Mitomycin C, Matrix metalloproteinases. The most radical surgical methods of treatment are based on therapeutic keratoplasty, the purpose of which is to excise the infectious focus of the cornea and restore its transparency through transplantation of donor corneal tissue, but this method has a number of disadvantages and limitations in its implementation. Autoconjunctival keratoplasty is the oldest method of treatment of progressive corneal ulcers and this method should be considered rather as temporary or preparatory before through keratoplasty, due to the lack of visual functions. The least radical and relevant surgical methods of CD treatment today are the use of Corneal Crosslinking, Microdiathermocoagulation, Cyanoacrylate glue, Amniotic membrane transplantation. The expansion of the arsenal of methods of influencing the microbial process of the cornea and their further study will allow for a quick response in response to the rapidly developing antibiotic resistance in the world.

1. 1, Park J., Lee K.M., Zhou H., Rabin M., Jwo K., Burton W.B., Gritz D.C. Community practice patterns for bacterial corneal ulcer evaluation and treatment. Eye Contact Lens. 2015;41(1):12–18. DOI: 10.1097/ICL.0000000000000059

2. Lin A., Rhee M.K., Akpek E.K., Amescua G., Farid M., Garcia-Ferrer F.J. Bacterial Keratitis Preferred Practice Pattern®. Ophthalmology. 2019;126(1):1–55 DOI: 10.1016/j.ophtha.2018.10.018

3. Termote K., Joe A.W., Butler A.L., McCarthy M., Blondeau J.M., Iovieno A., Holland S.P., Yeung S.N. Epidemiology of bacterial corneal ulcers at tertiary centres in Vancouver, B.C. Can J Ophthalmol. 2018;53(4):330–336. DOI: 10.1016/j.jcjo.2017.11.001

4. Jin H., Parker W.T., Law N.W., Clarke C.L., Gisseman J.D., Pflugfelder S.C., Wang L., Al-Mohtaseb Z.N. Evolving risk factors and antibiotic sensitivity patterns for microbial keratitis at a large county hospital. Br J Ophthalmol. 2017;101(11):1483–1487. DOI: 10.1136/bjophthalmol-2016-310026

5. Herretes S., Wang X., Reyes J.M. Topical corticosteroids as adjunctive therapy for bacterial keratitis. Cochrane Database Syst Rev. 2014;10(10):CD005430. DOI: 10.1002/14651858

6. Srinivasan M., Mascarenhas J., Rajaraman R., Ravindran M., Lalitha P., Glidden D.V., Ray K.J., Hong K.C., Oldenburg C.E., Lee S.M., Zegans M.E., McLeod S.D., Lietman T.M., Acharya N.R. Steroids for Corneal Ulcers Trial Group. Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT). Arch Ophthalmol. 2012;130(2):143–150. DOI: 10.1001/archophthalmol.2011.315

7. Ray K.J., Srinivasan M., Mascarenhas J., Rajaraman R., Ravindran M., Glidden D.V., Oldenburg C.E., Sun C.Q., Zegans M.E.., McLeod S.D., Acharya N.R., Lietman T.M. Early addition of topical corticosteroids in the treatment of bacterial keratitis. JAMA Ophthalmol. 2014;132(6):737–741. DOI: 10.1001/jamaophthalmol.2014.292

8. Lalitha P., Srinivasan M., Rajaraman R., Ravindran M., Mascarenhas J.., Priya J.L., Sy A., Oldenburg C.E., Ray K.J., Zegans M.E., McLeod S.D., Lietman T.M., Acharya N.R. Nocardia keratitis: clinical course and effect of corticosteroids. Am J Ophthalmol. 2012;154(6):934–939.e1. DOI: 10.1016/j.ajo.2012.06.001

9. Tallab R.T., Stone D.U. Corticosteroids as a therapy for bacterial keratitis: an evidence based review of ‘who, when and why’. Br J Ophthalmol. 2016;100(6):731–735. DOI: 10.1136/bjophthalmol-2015-307955

10. Volkovich T.K. Protective factors of lacrimal fluid and their significance in the diagnosis of eye diseases. Vestnik of vitebsk state medical university = Vestnik vitebskogo gosudarstvennogo meditsinskogo universiteta. 2008;7(3):104–109 (In Russ.).

11. Trufanov S.V., Shakhbazyan N.P., Zaitsev A.V., Rozinova V.N. Surgical management of infectious keratitis. Annals of Ophthalmology = Vestnik oftal’mologii. 2021;137(4):128–135 (In Russ.).

12. Yarmolinskaya M.I., Molotkov A.S., Denisova V.M. Matrix metalloproteinases and inhibitors: classification, mechanism of action. Journal of obstetrics and women’s diseases = Zhurnal akusherstva i zhenskih bolezney. 2012;61(1):113–125 (In Russ.).

13. McElvanney A.M. Doxycycline in the management of pseudomonas corneal melting: Two case reports and a review of the literature. Eye Contact Lens. 2003;29:258–261. DOI: 10.1097/01.icl.0000086490.38331.58

14. Hassanpour K., ElSheikh R., Arabi A., Frank C., Elhusseiny A., Eleiwa T., Arami S., Djalilian A., Kheirkhah A. Peripheral Ulcerative Keratitis: A Review. J Ophthalmic Vis Res. 2022;17(2):252–275. DOI: 10.18502/jovr.v17i2.10797

15. Wakaki S., Marumo H., Tomioka K. Isolation of new fractions of antitumor mitomycins. Antibiot Chemother. 1958;8:228–240.

16. Carones F., Vigo L., Scandola E., Vacchini L. Evaluation of the prophylactic use of mitomycin C to inhibit haze formation after photorefractive keratectomy. J Cataract Refract Surg. 2002;28:2088–2095. DOI: 10.1016/s0886 3350(02)01701-7

17. Kwan B.W., Chowdhury N., Wood T.K. Combatting bacterial infections by killing persister cells with mitomycin C. Environ Microbiol. 2015;17:4406–4414. DOI: 10.1111/1462-2920.12873

18. Khlebtsov N.G. Optics and biophotonics of nanoparticles with plasmon resonance. Quantum electronics. 2008;38(6):504–529 (In Russ.).

19. Galanov A.I., Yurmazova T.A., Saveliev G.G., Buldakov M.A., Rudyk Yu.V., Letvyakov N.V., Nechaev K.A., Tuzikov S.A., Cherdyntseva N.V., Yavorovsky N.A. Development of a magnetically controlled system for the delivery of chemotherapy drugs based on nanoscale iron particles. Siberian Journal of Oncology = Sibirskiy onkologicheskiy zhurnal.. 2008;3(27):50–57 (In Russ.).

20. Ponomarev V.O., Kazaykin V.N., Lizunov A.V., Vokhmintsev A.S., Weinstein I.A., Rozanova S.M., Kirf M.V. Laboratory Analysis of the Anti Infectious Activity of Quantum Dots and Bioconjugates Based on Them in the Aspect of the Prospects for the Treatment of Inflammatory Diseases of the Eye. Experimental Research (Part 3). Ophthalmology in Russia. 2022;19(1):188–194 (In Russ.). DOI: 10.18008/1816-5095-2022-1-188-194

21. Ponomarev V.O., Kazaykin V.N., Lizunov A.V., Rozanova S.M., Kirf M.V., Tkachenko K.A. Laboratory Analysis of the AntiInfectious Activity of Quantum Dots and Bioconjugates Based on Them against a Potential Eye Pseudomonas Aeruginosa Infection. Experimental Research (Part 4). Ophthalmology in Russia. 2022;19(2):429–433 (In Russ.). DOI: 10.18008/1816-5095-2022-2-429-433

22. Ponomarev V.O., Kazaykin V.N., Tkachenko K.A., Vokhmintsev A.S., Weinstein I.A., Rozanova S.M., Kirf M.V., Marysheva S.V. Evaluation of Anti Infectious Activity of Bioconjugates Based on Quantum Dots CdTe / Cd MPA 710 and Levofloxacin against Staphylococcal Corneal Infection. Experimental Research. Ophthalmology in Russia. 2022;19(4):808–814 (In Russ.). DOI: 10.18008/1816-5095-2022-4-808-814

23. Courtney C.M., Goodman S.M., McDaniel J.A., Madinger N.E., Chatterjee A., Nagpal P. Photoexcited quantum dots for killing multidrug resistant bacteria. Nat. Mater. 2016;15:529–534. DOI: 10.1038/nmat4542

24. Reddy H.L. Dayan A.D., Cavagnaro J., Gad S.., Li J., Goodrich R.P. Toxicity testing of a novel riboflavin based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev. 2008:22:133–153. DOI: l0.l0l6/j.tmrv.2007.l2.003

25. Sorkin N., Varssano D. Corneal collagen crosslinking: a systematic review. Ophthalmologica. 2014;232(1):10–27. DOI: 10.1159/000357979

26. Müller L., Thiel M.A., Kipfer Kauer A.I., Kaufmann C. Corneal cross linking as supplementary treatment option in melting keratitis: a case series. Klin Monbl Augenheilkd. 2012;229(4):411–415. DOI: 10.1055/s-0031-1299420

27. Iseli H.P., Thiel M.A., Hafezi F., Kampmeier J., Seiler T. Ultraviolet A/riboflavin corneal cross linking for infectious keratitis associated with corneal melts. Cornea. 2008 Jun;27(5):590–594. DOI: 10.1097/ICO.0b013e318169d698

28. Makdoumi K., Mortensen J., Crafoord S. Infectious keratitis treated with corneal crosslinking. Cornea. 2010 Dec;29(12):1353–1358. DOI: 10.1097/ICO.0b013e3181d2de91

29. Makdoumi K., Mortensen J., Sorkhabi O., Malmvall B.E., Crafoord S. UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2012;250(1):95–102. DOI: 10.1007/s00417-011-1754-1

30. Micelli Ferrari T., Leozappa M., Lorusso M., Epifani E., Micelli Ferrari L. Escherichia coli keratitis treated with ultraviolet A/riboflavin corneal cross linking: a case report. Eur J Ophthalmol. 2009;19(2):295–297. DOI: 10.1177/112067210901900221

31. Hafezi F., Randlcman B. PACK CXL: defining CXL for infectious keratitis. J Refract Surg. 2014;30(7):438–439. DOI: 10.3928/1081597X-20140609-01

32. Knyazer B., Krakauer Y., Baumfeld Y., Lifshitz T., Kling S., Hafezi F. Accelerated Corneal Cross Linking With Photoactivated Chromophore for Moderate Therapy-Resistant Infectious Keratitis. Cornea. 2018 Apr;37(4):528–531. DOI: 10.1097/ICO.0000000000001498

33. Saini S., Singh S., Dwivedi K., Singh S., Kumar S., Rana J. Photo-activated chromophore for infectious keratitis cross linking and its efficacy as a treatment modality in managing microbial keratitis. Indian J Ophthalmol. 2022;70(5):1571–1577. DOI: 10.4103/ijo.IJO_2693_21

34. Ting D.S.J., Henein C., Said D.G., Dua H.S. Photoactivated chromophore for infectious keratitis — Corneal cross linking (PACK CXL): A systematic review and meta analysis. Ocul Surf. 2019;17(4):624–634. DOI: 10.1016/j.jtos.2019.08.006

35. Varenko O.A. Comparative study of cryoapplication and diathermocoagulation in ulcerative keratitis. Ophthalmology. Kiev; 1973: Р. 42–46 (In Russ.).

36. Kasparova E.A. Modern treatments for purulent corneal ulcers. Annals of Ophthalmology = Vestnik oftal’mologii. 2016;132(5):125–135 (In Russ.). DOI: 10.17116/oftalma20161325125-135

37. Kasparova E.A., Zaitsev A.V., Kasparova Evg. A, Marchenko N.R. Combined use of microdiathermocoagulation and local express autocytokine therapy in the treatment of superficial infectious corneal ulcers. Annals of Ophthalmology = Vestnik oftal’mologii. 2012;128(6):50–53 (In Russ.).

38. Kasparova E.A., Zaitsev A.V., Kasparova E.A., Kasparov A.A. Microdiathermocoagulation in the treatment of infectious corneal ulcers. Оphthalmology in Russia = Oftal’mologiya.. 2016;13(3):157–162 (In Russ.). DOI: 10.18008/1816-5095-2016-3-157-162

39. Vote B.J., Elder M.J. Cyanoacrylate glue for corneal perforations: A description of a surgical technique and a review of the literature. Clin Exp Ophthalmol. 2000;28:437–442. DOI: 10.1046/j.1442-9071.2000.00351.x

40. Bhende S., Rothenburger S., Spangler D.J., Dito M. In vitro assessment of microbial barrier properties of Dermabond topical skin adhesive. Surg Infect (Larchmt). 2002;3(3):251–257. DOI: 10.1089/109629602761624216

41. Kiyoo N. Interaction between corneal invasion of polymorphonuclear leukocytes and corneal epithelium. Nippon Ganka Gakkai Zasshi. 1990;94:445–456.

42. Eiferman R.A., Snyder J.W. Antibacterial effect of cyanoacrylate glue. Arch Ophthalmol (Chicago, Ill: 1960) 1983;101:958–960. DOI: 10.1001/ar-chopht.1983.01040010958022

43. de Almeida Manzano R.P., Naufal S.C., Hida R.Y., Guarnieri L.O., Nishiwaki-Dantas M.C. Antibacterial analysis in vitro of ethyl cyanoacrylate against ocular pathogens. Cornea. 2006;25:350–351. DOI: 10.1097/01.ico.0000183490.16131.e3

44. Singh R.B., Zhu S., Yung A., Dohlman T.H., Dana R., Yin J. Efficacy of Cyanoacrylate Tissue Adhesive in the Management of Corneal Thinning and Perforation Due to Microbial Keratitis. Ocul Surf. 2020 Oct;18(4):795–800. DOI: 10.1016/j.jtos.2020.08.001

45. Yin J., Singh R.B., Al Karmi R., Yung A., Yu M., Dana R. Outcomes of Cyanoacrylate Tissue Adhesive Application in Corneal Thinning and Perforation. Cornea. 2019;38(6):668–673. DOI: 10.1097/ICO.0000000000001919

46. Malhotra C., Jain A.K. Human amniotic membrane transplantation: Different modalities of its use in ophthalmology. World J Transplant. 2014;4:111–121. DOI: 10.5500/wjt.v4.i2.111

47. Dua H.S., Gomes J.A., King A.J., Maharajan V.S. The amniotic membrane in ophthalmology. Surv Ophthalmol. 2004;49(1):51–77. DOI: 10.1016/j.survophthal.2003.10.004

48. Lee S.H., Tseng S.C. Amniotic membrane transplantation for persistent epithelial defects with ulceration. Am J Ophthalmol. 1997;123:303–312. DOI: 10.1016/s0002-9394(14)70125-4

49. Chen J.H., Ma D.H., Tsai R.J. Amniotic membrane transplantation for pseudomonal keratitis with impending perforation. Chang Gung Med J. 2002;25(3):144–152.

50. Mohan S., Budhiraja I., Saxena A., Khan P., Sachan S.K. Role of multilayered amniotic membrane transplantation for the treatment of resistant corneal ulcers in North India. Int Ophthalmol. 2014;34:485–491. DOI: 10.1007/s10792-013-9834-3

51. Sudalin A.V., Batmanov Yu.E. Application of keratoplasty and conjunctival plasty in the treatment of deep keratitis (Literature review). Russian Medical Journal. Clinical Ophthalmology = Rossiyskiy medicinskiy zhurnal. Klinicheskaya oftal’mologiya. 2003;4(1):1 (In Russ.).

52. Khodadoust A., Quinter A.P. Microsurgical approach to the conjunctival flap. Arch Ophthalmol. 2003;121:1189–1193. DOI: 10.1001/archopht.121.8.1189

53. Donnenfeld E.D., Solomon R., Perry A. Therapeutic keratoplasty. In: Krachmer J.J., Mannis M.J., Holland E.J., editors. Cornea. St. Louis: Mosby Year Book Inc; 2005. P. 1593–1603.

54. Nubile M., Dua H.S., Lanzini M. In vivo analysis of stromal integration of multilayer amniotic membrane transplantation in corneal ulcers. Am J Ophthalmol. 2011:151:809–822. DOI: 10.1016/j.ajo.2010.11.002

55. Kasparov A.A., Sadikhov A.K., Malozhen S.A. Treatment of purulent corneal ulcers. Annals of Ophthalmology = Vestnik oftal’mologii. 1987;103(6):67–71 (In Russ.).

56. Malik S.R., Singh G. Therapeutic keratoplasty in Pseudomonas pyocyaneus corneal ulcers. Br J Ophthalmol. 1971;55(5):326–330. DOI: 10.1136/bjo.55.5.326

57. Sharma N., Jain M., Sehra S.V.., Maharana P., Agarwal T., Satpathy G., Vajpayee R.B. Outcomes of therapeutic penetrating keratoplasty from a tertiary eye care centre in northern India. Cornea. 2014;33(2):114–118. DOI: 10.1097/ICO.0000000000000025

58. Kumar Sahu S., Das S., Sharma S., Sahu K. Clinico-Microbiological Profile and Treatment Outcome of Infectious Scleritis: Experience from a Tertiary Eye Care Center of India. Int J Inflam. 2012;2012:1–8. DOI: 10.1155/2012/753560

59. Ti S.E., Scott S.J., Janardhanan P., Tan D.T.H. Therapeutic keratoplasty for advanced suppurative keratitis. Am J Ophthalmol. 2007;143(5):755–762. DOI: 10.1016/j.ajo.2007.01.015

60. Shi W., Liu M., Gao H., Li S., Xie L. Perioperative treatment and prognostic factors for penetrating keratoplasty in Acanthamoeba keratitis unresponsive to medical treatment. Graefes Arch Clin Exp Ophthalmol. 2009;247(10):1383–1388. DOI: 10.1007/s00417-009-1103-9

61. Al Shehri A., Jastaneiah S., Wagoner M.D. Changing trends in the clinical course and outcome of bacterial keratitis at King Khaled Eye Specialist Hospital. Int Ophthalmol. 2009;29(3):143–152. DOI: 10.1007/s10792-008-9206-6

62. Ting D.S.J., Cairns J., Gopal B.P., Ho C.S., Krstic L., Elsahn A., Dua H.S. Risk Factors, Clinical Outcomes, and Prognostic Factors of Bacterial Keratitis: The Nottingham Infectious Keratitis Study. Med. 2021;8:715118. DOI: 10.3389/fmed.2021.715118

63. Ting D.S.J., Ghosh S. Acute corneal perforation 1 week following uncomplicated cataract surgery: the implication of undiagnosed dry eye disease and topical NSAIDs. Ther Adv Ophthalmol. 2019; Aug:12;11:2515841419869508. DOI: 10.1177/2515841419869508

64. Khoo P., Cabrera Aguas M.P., Nguyen V., Lahra M.M., Watson S.L. Microbial keratitis in Sydney, Australia: risk factors, patient outcomes, and seasonal variation. Graefes Arch Clin Exp Ophthalmol. 2020;258(8):1745–1755. DOI: 10.1007/s00417-020 04681 0